Reference number(s)
2240-H

SPECIALTY QUANTITY LIMIT PROGRAM

IDHIFA (enasidenib)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for the treatment of all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	FDA-recommended dosing	Standard Limit
Idhifa (enasidenib) 100 mg tablet	Acute myeloid leukemia: The recommended dose is 100 mg orally once daily. Dose modifications: • For elevation of bilirubin greater than 3 times the upper limit of normal sustained for ≥ 2 weeks without elevated transaminases or other hepatic disorders: Reduce Idhifa dose to 50 mg daily. Resume Idhifa at 100 mg daily if bilirubin elevation resolves to less than 2 times upper limit of normal • For Grade 3 or higher toxicity considered related to treatment including tumor lysis syndrome (not including differentiation syndrome and noninfectious leukocytosis): Interrupt Idhifa until toxicity resolves to Grade 2 or lower. Resume Idhifa at 50 mg daily; may increase to 100 mg daily if toxicities resolve to Grade 1 or lower.	30 tablets per 30 days
Idhifa (enasidenib) 50 mg tablet		30 tablets per 30 days

III. REFERENCE

1. Idhifa [package insert]. Summit, NJ: Celgene Corporation; August 2017.